Posted by Michael Wonder on 27 Apr 2020
ICER releases evidence report on treatments for cystic fibrosis
27 April 2020 - Evidence on Trikafta provides high confidence of a substantial net health benefit for patients; additional benefits accrue for family members and society.
The Institute for Clinical and Economic Review today released an Evidence Report assessing the comparative clinical effectiveness and value of elexacaftor with tezacaftor and ivacaftor (Trikafta, Vertex Pharmaceuticals) for the treatment of patients with cystic fibrosis (CF).
ICER also examined new data that have become available since its May 2018 review of three related CF treatments: ivacaftor (Kalydeco, Vertex), lumacaftor/ivacaftor (Orkambi, Vertex), and tezacaftor/ivacaftor (Symdeko, Vertex).
